Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
about
Dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitusGlucagon and heart in type 2 diabetes: new perspectivesAssessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversionCardiovascular safety of anti-diabetic drugsThe Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical TrialsPharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populationsDipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studiesDipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three StudiesAntidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesCurrent perspectives on cardiovascular outcome trials in diabetesStrategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseUpdate on the treatment of type 2 diabetes mellitusClosing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyondPractical combination therapy based on pathophysiology of type 2 diabetesRisk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study.SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia.Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.The regulatory role of DPP4 in atherosclerotic disease.Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort studyDipeptidyl Peptidase-4 Inhibitor Alarms: Is Heart Failure Caused by a Class Effect?Letter: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J 2015;39:247-52).Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study.Cardiovascular effects of the incretin-based therapy: the good, the bad, or the ugly?Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.NPY1-36 and PYY1-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trialCardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical ConsiderationsComparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy usersCardiovascular effects of dipeptidyl peptidase-4 inhibitors.Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice.PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment.Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease.An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease.
P2860
Q24185805-FA0439AF-2DAA-4516-89E0-712ADC9A1DEFQ26738580-C03C9D45-EA7C-479D-B3C7-BCF8A1DBD41FQ26740171-F18C5035-BC93-4E18-8F45-FF6B00D57577Q26741082-25D6A79E-4A92-43DA-8CD2-628B1D11B435Q26748870-79234024-C9E4-4D21-A6C4-652605B699F8Q26749524-7A1E39AD-0242-4CC1-9A88-C9E966A5CA7FQ26765047-EBA8B420-7976-4199-AD58-FD956337DDA6Q26777177-E75A6CE9-3385-4F46-BA27-06180D8A5424Q26785454-C4ADFBBF-16F4-4491-8069-BCB84ECDC792Q28066006-801A2B08-1B93-4E71-90E1-D4211141F410Q28069065-3ABF5CB2-4F37-41B3-A564-D98C6B09EEC0Q28073342-2E22A35C-83E0-430D-80E7-DCFCFACB3CA0Q28075848-AEDC0041-B1D1-44C7-A148-2C17B7E9A578Q28076530-0B15FF25-DE3C-4700-9F9D-D57A3DFCB894Q30234586-A7C23FBC-33A8-468B-9572-E91B9AB1E6D8Q30238791-D70706F1-3665-47B6-A668-37C30D72190CQ30240823-C5A34094-3C18-402B-8369-586009518611Q30250020-1723D1EB-48A7-4A0F-9298-76741B1AF4AEQ30846870-E750EE71-EBEA-4660-97E6-2CC825D3BBE9Q33660548-D64987C6-90EF-45E8-966A-EA82D3D95794Q33732627-5374A53A-581F-4337-88BE-B5B978096386Q33805518-7A760D9C-E5F4-4A22-8415-052F207F47BAQ33815573-62C08D5F-560F-4C8C-8F96-92170541CE6EQ33833732-A0D753CC-2D69-4BC3-BFA1-AC475E758A43Q35790625-4FEA0824-45D4-416E-A91E-F521500AA29DQ35976501-EDA54ECD-4F91-4432-AD99-B9DD2C57471DQ36119669-C76F8768-D62B-4E37-9F98-F1BD301F4291Q36232737-502BACE2-6496-4219-B5B8-1F45063270C5Q36327126-980E5B4E-5905-4669-8582-242015A84D1EQ36338382-91F309A1-28A1-4C52-A96A-F3877A2C213FQ36339460-C9F8DC73-EAF4-4540-9AE4-61EEAAE6ECCCQ36820255-58C5156A-2CB5-4152-80F9-10428E046D11Q36964223-F74F420D-BC99-4396-9C9E-BB3D5F9D7726Q37011769-546B0907-6EB8-4C18-B41B-0B00D0508D7CQ37077942-EF33E1AC-2B26-4419-BB0A-EBDF62AE3EC6Q37079289-C18C9B99-C3F5-46D1-8C78-0A8BD67705CDQ37080167-516DC163-A278-4568-9CFA-6DE76C8B627CQ37101005-CDF8D6C1-60D3-4992-9A7D-55229BB1AEC0Q37103963-0A8ED9B9-0AD3-4302-BD8A-23702C6B2A6AQ37141607-6788DECE-CFAC-4F4E-8DEC-3A456511B9C5
P2860
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Heart failure and mortality ou ...... andomised, double-blind trial.
@en
type
label
Heart failure and mortality ou ...... andomised, double-blind trial.
@en
prefLabel
Heart failure and mortality ou ...... andomised, double-blind trial.
@en
P2093
P921
P1433
P1476
Heart failure and mortality ou ...... andomised, double-blind trial.
@en
P2093
Alfonso T Perez
Christopher P Cannon
Craig Wilson
Cyrus R Mehta
EXAMINE Investigators
George L Bakris
Penny R Fleck
Stuart Kupfer
Venu Menon
P304
P356
10.1016/S0140-6736(14)62225-X
P407
P50
P577
2015-03-10T00:00:00Z